Is there any obvious resistance mechanism to Sotorasib?

Sotorasib is a targeted drug targeting the KRAS G12C mutation and has been approved for the treatment of patients with non-small cell lung cancer (NSCLC) carrying this mutation. Although sotoracib has shown good initial efficacy in some patients, the emergence of resistance mechanisms has become an important factor limiting its long-term efficacy.

The secondary mutation of KRAS G12C itself is a key mechanism for the development of resistance to sotoraxib. In some patients, after a period of treatment, tumor cells may pass through other loci of the KRAS gene (such as G13D, < /span>Y96D, etc.), which changes the conformation of KRAS protein and reduces the binding ability of sotoraxib, thus leading to drug resistance. Such mutations may be an "escape" mechanism arising from treatment stress.

Activation of alternative signaling pathways is also a common drug resistance mechanism. For example, activation of pathways such as EGFR, MET, PI3K, and BRAF can bypass KRAS inhibition and continue to drive tumor cell growth and proliferation. This type of "bypass activation" resistance usually occurs during the evolution of tumor clones, allowing cancer cells to survive and progress even if KRAS G12C is effectively inhibited.

Phenotypic switching of tumors or changes in the cellular microenvironment may also lead to drug resistance. For example, some NSCLC patients may develop small cell lung cancer transformation or mesenchymal transformation after receiving sotoracib treatment, thereby reducing sensitivity to KRAS G12C inhibitors. In addition, immune evasion mechanisms in the tumor microenvironment may also weaken the therapeutic effect of drugs.

Faced with these resistance mechanisms, clinical combination treatment strategies are gradually being explored to delay or overcome resistance. For example, combining sotoracib with EGFR inhibitors, SHP2 inhibitors, or immunotherapy has shown promise in early clinical trials. In the future, more molecular typing and precise monitoring of drug resistance mechanisms will help to formulate individualized treatment strategies and improve the lasting efficacy of KRAS G12C targeted therapy.

Reference materials:https://www.drugs.com/